Strengthening the Regulatory Capacity of the National Health Surveillance Agency

• Grant number: 23/14263-5
• Support Opportunities: Scholarships abroad - Research Internship - Master's degree
• Start date: February 10, 2024
• End date: July 29, 2024
• Field of knowledge: Applied Social Sciences - Administration - Public Administration
• Principal Investigator: Elize Massard da Fonseca
• Grantee: Vitória Lopes de Oliveira Silva
• Supervisor: Pedro Miguel Dias Costa Coutinho Magalhaes
• Host Institution: Escola de Administração de Empresas de São Paulo (EAESP). Fundação Getúlio Vargas (FGV). São Paulo , SP, Brazil
• Institution abroad: Universidade de Lisboa, Portugal
• Associated to the scholarship: 22/16435-5 - Reforming health surveillance in Brazil, BP.MS

Abstract

Considering that the objective of the master's project is to analyze the process of strengthening the regulatory capacity of the National Health Surveillance Agency (Anvisa), currently recognized as the leading agency for drug regulation in Latin America, this research internship abroad aims to advance in the conceptual framework and data analysis. Specifically, the international internship will seek to enhance the analytical framework to understand the relationship between the independent regulatory agency, international institutions, and the regulated sector. Contact with Professors Pedro Magalhães and Luis de Sousa's framework and professors from the Institute of Social Sciences at the University of Lisbon will contribute to the analysis and interpretation of the data, considering explanatory arguments that include the choices of an independent bureaucracy, the potential capture of the regulatory process by private interests, or even adherence to international forums. The master's research uses a qualitative methodology and, process tracing technique, to analyze the institutionalization of Anvisa from a longitudinal perspective. The internship will also provide an opportunity to explore Portuguese and European pharmaceutical regulation, which has served as a model for Anvisa's decisions.